PFE Latest Headlines

Anti-vaccine group asks RFK Jr. to add more vaccine injuries to compensation program

at seekingalpha.com (Thu, 26-Mar 12:21 PM)

White House misses deadline for CDC director nominee

at seekingalpha.com (Wed, 25-Mar 4:24 PM)

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

at seekingalpha.com (Wed, 25-Mar 12:31 PM)

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pfizer (PFE) and Wave Life Sciences (WVE)

at www.tipranks.com (Tue, 24-Mar 7:30 AM)

Citi Remains a Hold on Pfizer (PFE)

at www.tipranks.com (Tue, 24-Mar 7:16 AM)

Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Idexx Laboratories (IDXX)

at www.tipranks.com (Tue, 24-Mar 6:50 AM)

Pfizer’s Lyme Disease Vaccine Candidate Achieves 73% Efficacy in Key Phase 3 Trial – Regulatory Submissions Planned

Market Chameleon (Mon, 23-Mar 7:09 AM)

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

at www.benzinga.com (Mon, 23-Mar 10:35 AM)

Dow Jumps Over 800 Points; Chicago Fed National Activity Index Declines In February

at www.benzinga.com (Mon, 23-Mar 10:22 AM)

Citi's large-cap stocks with negative ROE trends

at seekingalpha.com (Mon, 23-Mar 10:05 AM)

Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success

at www.tipranks.com (Mon, 23-Mar 8:14 AM)

Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate

at seekingalpha.com (Mon, 23-Mar 7:51 AM)

Pfizer’s Tilrekimig Shows Significant Efficacy in Atopic Dermatitis—Phase 3 Set to Accelerate

Market Chameleon (Mon, 9-Mar 7:12 AM)

PADCEV Plus Keytruda Shows Major Survival Benefit in Muscle-Invasive Bladder Cancer—A Potential Shift in Standard Care

Market Chameleon (Mon, 2-Mar 7:13 AM)

Pfizer Delivers Steady Growth Beyond COVID-19: 2025 Results Show 6% Revenue Increase in Core Portfolio and Strong Pipeline Momentum

Market Chameleon (Tue, 3-Feb 7:15 AM)